Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Vaccine for foot and mouth in five years, say researchers
Scientists hope to produce vaccine by end of five-year project

Leading research scientists have said they are confident a vaccine for foot-and-mouth disease (FMD) will be produced in the next five years.

Researchers from the Pirbright Institute and the universities of St Andrews, Leeds, Edinburgh and Dundee are working on a five-year project to form an effective vaccine for FMD type-O - the serotype that caused the 2001 UK outbreak.

The project, which hopes for a vaccine with improved responses, reduced need for revaccination, and eventually the development of a weapon against all known strains of the disease, has been part-funded by the Biotechnology and Biological Sciences Research Council (BBSRC).

Terry Jackson, team leader on the FMD project at Pirbright, said: "The significant thing is that the universities can use sub-genomic replicons. These replicons don't produce infectious virus, so they are perfectly safe to work on outside of our containment facility. The universities now have permission to use them and at the end of this we would be very disappointed if we did not have a vaccine using the live unattenuated virus."

The 2001 FMD virus outbreak lead to the deaths of seven million sheep and cattle, and was estimated to have cost the British economy around £8b.

Dr Jackson added: "Success would be massive. A lot of people who work at Pirbright would love to leave a legacy; we would love to leave behind something and say we made a difference."

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.